Inherited retinal diseases (IRDs) are a group of severe retinal degenerative diseases leading to permanent visual impairment. IRDs are the major cause of irreversible blindness in children and working age groups. Gene therapy is a new clinical treatment method and currently the only clear and effective treatment for IRDs, while, there are still risks in clinical research and application. How to standardize perioperative management and reduce the potential risks of treatment is one of the keys to ensure the safety and effectiveness of treatment. However, there is no systematic and standardized guidance on the perioperative management for IRDs gene therapy. Therefore, in order to standardize the perioperative management, the Fundus Disease Group of Ophthalmology Society of Chinese Medical Association and Chinese Medical Doctor Association organized domestic experts to put forward standardized opinions on the perioperative management of IRDs gene therapy in China after repeated discussion and combined with domestic and foreign research experience, so as to provide clinicians with reference and application in clinical research and practice.

Citation： Fundus Disease Group of Chinese Medical Association Ophthalmology Branch, Fundus Disease Committee of Chinese Medical Doctor Association Ophthalmology Branch. Expert consensus on the operative safety management and visual function evaluation index setting of gene therapy for inherited retinal diseases. Chinese Journal of Ocular Fundus Diseases, 2022, 38(8): 636-642. doi: 10.3760/cma.j.cn511434-20220808-00442 Copy